-+ 0.00%
-+ 0.00%
-+ 0.00%

Anterogen Seeks South Korean Approval for Phase 2 Trial of ANT-301

PUBT·10/26/2026 05:44:50
Listen to the news
Anterogen Seeks South Korean Approval for Phase 2 Trial of ANT-301
  • Anterogen submitted a Phase 2 trial amendment application for ANT-301 to South Korea’s drug regulator on Oct. 26, 2026.
  • The knee osteoarthritis trial targets Kellgren-Lawrence grade 3 patients, with planned enrollment of 63 participants, up to a maximum of 66.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anterogen Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261026900276), on October 26, 2026, and is solely responsible for the information contained therein.